Menu
No results found.
Weekly Share Price & Valuation Overview
Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which is in phase 1/2 clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel; and the Australasian Leukaemia and Lymphoma Group to expand the clinical development of vididencel as a maintenance treatment for AML. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- SEK 411.99M
- Enterprise Value Operating value: market cap + total debt − cash.
- SEK 334.76M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- SEK -1.44M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- SEK -0.03
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -2.42
- Shares Outstanding
- 52.08M
- Float Shares
- 14.07M
- Implied Shares Outstanding
- 52.08M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-22.55%
- ROA Return on assets: net income ÷ total assets.
-
-11.37%
- ROE Return on equity: net income ÷ shareholder equity.
-
-19.16%
- Revenue Growth Year-over-year revenue growth.
-
-51.90%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 2.55
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.03
- Total Cash Cash and equivalents.
- SEK 84.73M
- Total Debt Short + long-term interest-bearing debt.
- SEK 21.14M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- SEK -63.59M
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.